The consumer & scientific resource hub for pneumococcal disease


Educational Tools

Pneumococcal Disease Slide deck


2016 Pneumococcal Disease Guide for General Practitioners


15 June 2016: Click here
28 June 2016: Click here

Recently Published Articles

  1. Alderson MR. Status of research and development of pediatric vaccines for Streptococcus pneumoniae. Vaccine. 2016 Jun 3;34(26):2959-61. Full text
  2. Alqahtani AS. et al. Exploring barriers to and facilitators of preventive measures against infectious diseases among Australian Hajj pilgrims: cross-sectional studies before and after Hajj. Int J Infect Dis. 2016 Feb 10. pii: S1201-9712(16)00025-4. Full text
  3. Berical AC. et al. Pneumococcal Vaccination Strategies. An Update and Perspective. Ann Am Thorac Soc. 2016 Jun;13(6):933-44. Abstract
  4. Best EJ. et al. Pneumococcal vaccine impact on otitis media microbiology: A New Zealand cohort study before and after the introduction of PHiD-CV10 vaccine. Vaccine. 2016 Jul 19;34(33):3840-7. Abstract
  5. Chang MS, Woo JH. The prevention of pneumococcal infections. Clin Exp Vaccine Res. 2016 Jan;5(1):3-5. Full text
  6. Clarke E, Kampmann B, Goldblatt D. Maternal and neonatal pneumococcal vaccination – where are we now? Expert Rev Vaccines. 2016 Apr 18:1-13. Abstract
  7. Dagan R. et al. Prevention of early episodes of otitis media by pneumococcal vaccines might reduce progression to complex disease. Lancet Infect Dis. 2016 Apr;16(4):480-92. Abstract
  8. Daniels CC, Rogers PD, Shelton CM. A Review of Pneumococcal Vaccines: Current Polysaccharide Vaccine Recommendations and Future Protein Antigens. J Pediatr Pharmacol Ther. 2016 Jan-Feb;21(1):27-35.
    Full text
  9. de Kluyver R, Toms C. Enhanced Invasive Pneumococcal Disease Surveillance Working Group, for the Communicable Diseases Network Australia. Invasive pneumococcal disease surveillance Australia, 1 October to 31 December 2015. Commun Dis Intell Q Rep. 2016 Mar 31;40(1):E185-8.
    Full text
  10. Elberse KE. et al. Pneumococcal population in the era of vaccination: changes in composition and the relation to clinical outcomes. Future Microbiol. 2016;11(1):31-41. Abstract
  11. Esposito S. et al. Pneumococcal colonization in older adults. Immun Ageing. 2016 Jan 12;13:2. Full text
  12. Ewald H. et al. The Clinical Effectiveness of Pneumococcal Conjugate Vaccines: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Dtsch Arztebl Int. 2016 Mar 4;113(9):139-46. Full text
  13. Fay EE. et al. Survey of Obstetrics and Gynecology Residents Regarding Pneumococcal Vaccination in Pregnancy: Education, Knowledge, and Barriers to Vaccination. Infect Dis Obstet Gynecol. 2016;2016:1752379. Full text
  14. Frenck RW. et al. Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older. Vaccine. 2016 Jun 24;34(30):3454-62. Abstract
  15. Grau I. et al. Declining mortality from adult pneumococcal infections linked to children’s vaccination. J Infect. 2016 Apr;72(4):439-49. Abstract
  16. Hanada S. et al. Host Factors and Biomarkers Associated with Poor Outcomes in Adults with Invasive Pneumococcal Disease. PLoS One. 2016 Jan 27;11(1):e0147877. Full text
  17. Hayward S, Thompson LA, McEachern A. Is 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Combined With 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) Superior to PPSV23 Alone for Reducing Incidence or Severity of Pneumonia in Older Adults? A Clin-IQ. J Patient Cent Res Rev. 2016;3(2):111-115. Full text
  18. Isturiz RE. et al. Pneumococcal conjugate vaccine use in adults. Expert Rev Vaccines. 2016;15(3):279-93. Abstract
  19. Kawakami K. et al. Revaccination with 23-valent pneumococcal polysaccharide vaccine in the Japanese elderly is well tolerated and elicits immune responses. Vaccine. 2016 Jul 19;34(33):3875-81. Full text
  20. Klett-Tammen CJ. et al. Determinants of tetanus, pneumococcal and influenza vaccination in the elderly: a representative cross-sectional study on knowledge, attitude and practice (KAP). BMC Public Health. 2016 Feb 4;16:121. Abstract
  21. Kraicer-Melamed H, O’Donnell S, Quach C. The effectiveness of pneumococcal polysaccharide vaccine 23 (PPV23) in the general population of 50 years of age and older: A systematic review and meta-analysis. Vaccine. 2016 Mar 18;34(13):1540-50. Abstract
  22. Li Y. et al. Directed vaccination against pneumococcal disease. Proc Natl Acad Sci U S A. 2016 Jun 21;113(25):6898-903. Abstract
  23. Newall AT. et al. Retrospective economic evaluation of childhood 7-valent pneumococcal conjugate vaccination in Australia: Uncertain herd impact on pneumonia critical. Vaccine. 2016 Jan 12;34(3):320-7. Abstract
  24. Papadatou I, Spoulou V. Pneumococcal Vaccination in High-Risk Individuals: Are We Doing It Right? Clin Vaccine Immunol. 2016 May 6;23(5):388-95. Abstract
  25. Paradiso PR. Pneumococcal conjugate vaccine in adults: Let’s see what happens. Hum Vaccin Immunother. 2016 Jul 2;12(7):1906-7. Abstract
  26. Pingali SC. et al. Association Between Local Pediatric Vaccination Rates and Patterns of Pneumococcal Disease in Adults. J Infect Dis. 2016 Feb 15;213(4):509-15. Abstract
  27. Pletz MW. et al. Advances in the prevention, management, and treatment of community-acquired pneumonia. F1000Res. 2016 Mar 8;5. pii: F1000 Faculty Rev-300. Full text
  28. Prato R, Fortunato F, Martinelli D. Pneumococcal pneumonia prevention among adults: is the herd effect of pneumococcal conjugate vaccination in children as good a way as the active immunization of the elderly? Curr Med Res Opin. 2016;32(3):543-5. Abstract
  29. Ren S. et al. Rationale and design of a randomized controlled trial of pneumococcal polysaccharide vaccine for prevention of cardiovascular events: The Australian Study for the Prevention through Immunization of Cardiovascular Events (AUSPICE). Am Heart J. 2016 Jul;177:58-65. Abstract
  30. Schiffner-Rohe J. et al. Efficacy of PPV23 in Preventing Pneumococcal Pneumonia in Adults at Increased Risk–A Systematic Review and Meta-Analysis. PLoS One. 2016 Jan 13;11(1):e0146338. Full text
  31. Stoecker C. et al. Incremental Cost-Effectiveness of 13-valent Pneumococcal Conjugate Vaccine for Adults Age 50 Years and Older in the United States. J Gen Intern Med. 2016 Aug;31(8):901-8. Abstract
  32. Tashani M. et al. Barriers of vaccinations against serious bacterial infections among Australian Hajj pilgrims. Postgrad Med. 2016 Jun 9:1-7. Abstract
  33. van Hoek AJ, Miller E. Cost-Effectiveness of Vaccinating Immunocompetent ≥65 Year Olds with the 13-Valent Pneumococcal Conjugate Vaccine in England. PLoS One. 2016 Feb 25;11(2):e0149540. Full text



Receive the latest clinical and event information via email.